Results 191 to 200 of about 219,337 (367)

Von Willebrand factor and angiogenesis: basic and applied issues

Journal of Thrombosis and Haemostasis, 2017
A. Randi, M. Laffan
semanticscholar   +1 more source

Microthrombotic Complications of COVID-19 Are Likely Due to Embolism of Circulating Endothelial Derived Ultralarge Von Willebrand Factor (eULVWF) Decorated-Platelet Strings

, 2020
Nadarajah Varatharajah
openalex   +2 more sources

In Silico Assessment of Limited Blood Sampling Strategies for Individualised Pharmacokinetic‐guided Dosing of Efanesoctocog Alfa in Haemophilia A Patients

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel factor VIII (FVIII) concentrate with a unique molecular design that enables Von Willebrand Factor‐independent clearance in patients with haemophilia A. Limited sampling strategies (LSSs) are necessary to implement accurate pharmacokinetic (PK)‐guided dosing for efanesoctocog alfa in clinical practice.
Jelien den Hollander, Marjon H. Cnossen, Ron A. A. Mathôt   +2 more
wiley   +1 more source

Biochemistry and genetics of von Willebrand factor.

Annual Review of Biochemistry, 1998
Fred E. Cohen, S. B. Prusiner, D. G. Hardie, David Carling   +3 more
semanticscholar   +1 more source

Comparison of von Willebrand factor platelet‐binding activity assays: ELISA overreads type 2B with loss of HMW multimers [PDF]

, 2020
Attila Szederjesi, Luciano Baronciani, Ulrich Budde, Giancarlo Castaman, Paola Colpani, Andrew Lawrie, Yuan Liu, Robert R. Montgomery, Flora Peyvandi, Reinhard Schneppenheim, Jürgen Patzke, Imre Bodó   +11 more
openalex   +1 more source

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang, Natalie Johnston, Daniel Echelman, Stacy E. Croteau   +3 more
wiley   +1 more source

Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity

Alimentary Pharmacology and Therapeutics, 2018
M. Mandorfer, P. Schwabl, R. Paternostro, K. Pomej, D. Bauer, J. Thaler, Cihan Ay, P. Quehenberger, Monika Fritzer-Szekeres, Markus Peck-Radosavljevic, Michael Trauner, T. Reiberger, A. Ferlitsch   +12 more
semanticscholar   +1 more source

Carotid Intima‐Media Thickness as a Marker of Subclinical Atherosclerosis in Adolescents With Severe Haemophilia

Haemophilia, EarlyView.
ABSTRACT Background The clinical focus of haemophilia has expanded beyond bleeding outcomes to encompass long‐term comorbidities such as cardiovascular disease (CVD). However, it remains unclear when vascular changes begin in this population. Carotid intima‐media thickness (cIMT), a validated, non‐invasive marker of subclinical atherosclerosis, may ...
Alyson Trillo, Juanita Hunter, Audrey Ofir, Jamie Shoag, Joanna A. Davis, Fernando F. Corrales‐Medina   +5 more
wiley   +1 more source

Enhancing the Evidence for Care in Underserved Bleeding Disorders Communities

Haemophilia, EarlyView.
ABSTRACT Background Major advances in haemophilia care have not translated equitably across all populations. Individuals with rare bleeding disorders (RBDs), people living in low‐ and lower‐middle‐income countries (LMICs) and women and girls with inherited bleeding disorders (WGWBD) continue to face significant diagnostic, therapeutic and research ...
Johnny Mahlangu
wiley   +1 more source

Structure and multiple functions of von Willebrand factor. [PDF]

Haematologica
Haberichter SL, O'Donnell JS.
europepmc   +1 more source